Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Spark Therapeutics, Inc.    ONCE

SPARK THERAPEUTICS, INC.

(ONCE)
SummaryQuotesNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Spark Therapeutics : Roche extends offer deadline for Spark Therapeutics again

share with twitter share with LinkedIn share with facebook
share via e-mail
11/22/2019 | 01:26am EST
FILE PHOTO: Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

Roche has again extended the deadline for its tender offer for Spark Therapeutics, the Swiss drugmaker said on Friday, saying U.S. and British anti-trust authorities needed more time to review the deal.

The offer, which was originally due to expire on Nov. 25, has now been extended to Dec. 10. All terms and conditions of the offer remain the same, Roche said. So far 14.8% of the shares were tendered.

Roche has put back the deadline several times since it announced the $4.3 billion offer to buy the gene therapy company in February.

(Reporting by John Revill; Editing by Michael Shields)

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING AG -3.95% 309.7 Delayed Quote.-1.37%
SPARK THERAPEUTICS, INC. 0.00%End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SPARK THERAPEUTICS, INC.
2019Trouble for Boeing, Netflix expands, Amazon toughens up against Fedex…
2019SPARK THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Compl..
AQ
2019SPARK THERAPEUTICS : Roche and Spark Therapeutics, Inc. announce closing of inve..
AQ
2019Roche to complete $4.3 billion Spark deal as regulators give all clear
RE
2019Roche to complete $4.3 billion Spark deal as regulators give all clear
RE
2019SPARK THERAPEUTICS : Roche clears UK hurdle in $4.3 billion Spark deal, U.S. rev..
RE
2019EUROPE : European shares dragged down by Tullow Oil and weak China export data
RE
2019ROCHE : Extends Tender Offer for Spark Therapeutics
DJ
2019SPARK THERAPEUTICS : Swiss drugmaker Roche again extends $4.3 billion Spark offe..
RE
2019SPARK THERAPEUTICS : Roche extends offer deadline for Spark Therapeutics again
RE
More news
Chart SPARK THERAPEUTICS, INC.
Duration : Period :
Spark Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Stephen W. Webster Chief Financial & Accounting Officer
Federico Mingozzi Chief Scientific Officer
Bruce Resnick Director
Sean A. Johnston Director
Joseph W. La Barge Chief Legal Officer
Sector and Competitors
1st jan.Capitalization (M$)
SPARK THERAPEUTICS, INC.0.00%4 375
GILEAD SCIENCES11.82%87 646
VERTEX PHARMACEUTICALS2.32%58 084
REGENERON PHARMACEUTICALS14.95%48 395
WUXI APPTEC CO., LTD.15.07%24 967
GENMAB A/S2.73%14 596